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Bioethics and large-scale biobanking:  






Like most bioethical discussion, examination of human biobanks has been largely 
framed in terms of research subjects’ rights, principally informed consent, with some 
gestures toward public benefits. However, informed consent is for the competent, 
rights-bearing individual: focussing on the individual, it thus neglects social, 
economic and even political matters; focussing on the competent rights-bearer, it does 
not serve situations where consent is plainly inappropriate (eg, the young child) or 
where coercion can obviously be justified (the criminal). 
 
Using the British experience of large-scale biobanking, I argue that the focus on 
consenting individuals distorts our ways of thinking about biobanks and has serious 
practical ramifications. This becomes clear if we contrast the case of adult biobanks 
intended for medical research with two other forms of biobanking. Thus child cohort 
studies – vital for sound scientific investigation of the interplay of genetics and 
environment in health – have been very badly funded next to adult studies. On the 
other hand, forensic databases have attracted massive investment, but little debate – 
partly owing to a sense that here, at least, is a case where consent is not relevant. 
 
Contrasting these central types of biobanking, I will suggest that there are powerful 
factors at work in limiting ‘ethics’ to individual rights. Projects of this size should 
direct our attention to more overtly political questions concerning priority setting and 




In this paper I wish to cast a critical eye at the way in which we – meaning both 
bioethicists and practitioners – frame ethical and bioethical discussion. A slow swell 
of protest has been gathering, from many directions, against the idea that protection of 
individual rights should be the central focus of bioethical concern.1 Nonetheless, 
standard assumptions, and powerful institutions, continue to equate (bio)ethics with 
the protection of individual patients or research subjects – protections most often 
framed in terms of confidentiality and informed consent.2
 
My discussion will be particularly concerned with large-scale biobanks, and the 
difficulties that we have experienced in deciding – or discovering – the principles by 
which they might be regulated and governed. Part of our difficulty has come from the 
fact that biobanking is in fact highly variegated in form: many different sorts of 
biobank exist, but those that have attracted the most attention are as yet more intent 
than reality. Especially in the UK, but also beyond, debate has centred around two 
examples of large-scale biobanking for medical research which are either – in the case 
of UK Biobank – still being planned, or – the Icelandic database – only partly 
realised. One difficulty, then, is that we have spoken more about intended projects – 
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and not exploited the experience we do have with biobanking. The second is that 
public and policy discourse, and to some extent bioethical reflection, has taken its 
orientation from now conventional moral categories of medical research ethics. So we 
have heard a great deal more about principles focussing on individual rights and 
protections – informed consent and confidentiality – than other principles or ethical 
frameworks. This is surely very odd, given the necessarily collective nature of these 
projects.3
 
This suggests two routes toward greater clarity about the legitimating principles for 
human biobanking. First, that we ask whether our dominant focus on individual 
rights, so clearly ill-suited to reflecting on large-scale collaborative research, might 
serve other purposes beyond the protection of individual rights. Second, that we give 
attention to the already existing, and in some cases highly successful, examples of 
biobanking, and how far individual rights provide a framework for ethical reflection 
on these. 
 
I begin by examining how it may be that we have come to identify ethics with a focus 
on individual rights, above all informed consent, and the different purposes and 
interests this focus may serve. I then describe some notable examples of large-scale 
biobanks, and examine how a focus on individual rights hinders us in appreciating the 
ethical issues that they raise. I conclude with the contention that, although some 
organised interests may be motivated to separate (bio)ethics from questions of 
undoubted political significance, a concern with ethics must point us in exactly the 
opposite direction. To focus on individual rights may actually undermine individual 
rights and interests, in ways that benefit some organised interests, because important 
social, political and scientific questions are left out of consideration.4
 
Individual rights and informed consent 
 
The main planks of medical research ethics after the second world war are well-
known, first and foremost in the form of the World Medical Association’s Declaration 
of Helsinki (1962). Against the horrifying abuses of individuals that were perpetrated 
in Nazi Germany and Japan, and against increasing awareness of serious on-going 
abuses within democracies such as the USA or even Sweden, two ideas were made 
central to medical research ethics. The first was the free and voluntary consent of the 
individual research subject. This coincided, of course, with Western societies’ 
increasing emphasis upon the informed consent of patients to any medical 
interventions they might undergo. The second measure was ethical review of research 
trials via ‘research ethics committees’ or ‘institutional review boards.’ Of course, it 
was not only that ‘experiments’ were done that no-one in their right mind would 
consent to, but – and this fact gets forgotten when we focus on informed consent 
alone – the research (or so-called research) should never have been conceived of in 
the first place. To these two key planks of research ethics we should also add 
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The individual rights, to confidentiality but above all to informed consent, have come 
to dominate ethical thought about medical research. This may be an unfair 
generalisation so far as academic bioethical reflection is concerned, long since 
advanced beyond its ‘four principles’ stages. But so far as a generalisation can be fair, 
I suggest this reasonably applies to the teaching of bioethics, to common perceptions 
of (bio)ethics, and to the avowedly ‘ethical’ components of policy thinking. Simply 
and crudely: when most people, and most organisations, think of ethics they think of 
ethical safeguards for individuals. The background assumption is that research is a 
good, if not a good in itself; and therefore all that ethics need do is ensure that the 
rights of participants are respected: consent and confidentiality. While research ethics 
committees continue to scrutinise research proposals from the point of view of 
scientific soundness and not just individual rights, we still find a natural and 
unfortunate division between ‘good science’ and ‘good conduct.’ More than this, 
these standard mechanisms to protect rights and to ensure that research is well-
conceived do not answer as to which research is pursued, which avenues ignored, and 
how research is organised. Not all research, after all, is equally desirable. 
 
It is a difficult question, why we should have come to think that the ethics of medical 
research can be decided in terms of safeguards for individual rights, above all 
informed consent. I would like to suggest that a diverse range of factors has been at 
work. Some of these undoubtedly reflect good and valid reasons for insisting on the 
importance of consent to medical research (although my own view is that consent 
should not be necessary for every sort of research5). But there are other factors at 
work here, that suggest that our focus on consent is a little too convenient: that it may 
fit too neatly with some common habits of Western thought, that such a focus may in 
fact serve organised interests which can work against the public good and even the 
good of individual research subjects. We can view informed consent as a powerful 
case study of how any principle – however valid it may be – is always more 
complicated and ambivalent in its practice than we might like to think. 
 
The difficulty of this question – why we should so often focus on informed consent – 
is only enhanced when we remember some obvious and well-known difficulties that 
attend it. Allow me to mention only a few.6
 
• As study upon study has shown, the ‘informed’ aspect of informed consent 
proves to be rather fleeting. People persistently ignore, forget, misunderstand 
the information that researchers provide them with; quite often they forget that 
they have consented to a research project at all. There is the further question as 
to whether the promises and information that potential research subjects are 
given are actually accurate, which points us to the need for institutional 
oversight of this, and other, aspects of how any research project is conducted. 
It seems, indeed, that many research ethics committees have come to see their 
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• Informed consent is irrelevant to many groups of (potential) research subjects. 
It is impossible with infants and problematic with older children. It is also 
pretty much useless for the retarded, the senile, the demented and for some 
types of mental illness.7 Indeed, as evidence for my claim that informed 
consent tends to orient our thinking and practice, sometimes harmfully, we 
might recall the well-known problem of non-research that arises here. The 
effects of many drugs on children are simply not researched or documented, 
vastly increasing the risk when they are thought necessary to treat a child. 
Instead of organised research, then, we have a plethora of unorganised, 
unreported and unsynthesised experiments on people who are incompetent to 
consent. 
 
• When we focus upon individual consent to research, we also neglect the 
importance of statutory research, that poses few risks to individuals but is 
essential to the running and improvement of collective health provision. 
Examples include: audits of medical practitioners, teams and organisations; 
monitoring for cost-effectiveness; research concerning public health and 
epidemiology; follow-up of medical interventions for side-effects and 
efficacy; monitoring of notifiable diseases; and the keeping of disease 
registers. These have usually not been subject to informed consent and their 
value would be undermined if they were, in terms of not only incompleteness 
but also probable selectivity in opting out.8 One way such research has been 
defended from the requirement of informed consent is by the anonymisation of 
subjects’ samples and/or information; but this is not always possible or 
desirable. 
 
• Informed consent is about individuals, and one of its purposes is to empower 
individuals against organised and expert researchers. However, it can actually 
obscure this power relationship. Requiring consent will not, by itself, alter the 
fact that uncoordinated individuals are always subject to the power of 
organised groups or institutions. This fact may not be problematic so long as 
we can reasonably take the benefits and organisation of research for granted. 
But for many reasons this is not something we should do. One important 
advance in the organisation of medical research occurred with the advent of 
HIV/AIDS. As we know, this disease was very badly researched to begin with, 
largely because of prejudice against the groups who were worst affected. One 
response was political organisation among some of those groups, to lobby for 
and even fund the necessary research. As became clear, not all the institutions 
involved in medical research are operating in the public interest; indeed, we 
should be well aware that no organisation can be trusted reliably to serve that 
interest without active public scrutiny. 
 
All these well-known difficulties only sharpen the question: why should informed 
consent have become so definitive of medical and research ethics – not just in 
(philosophical) bioethics but above all in how ethics is understood by practitioners, 
policy-makers and their institutions? 
 
In the philosophical context, consent has a natural fit with certain framing assumption 
of much ethical theory. Key among these is our customary focus on individual duties, 
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individual rights, and respect for the choosing subject via the elusive, multivalent 
notion of autonomy. This relates to a tendency to focus on the competent, rights-
bearing adult, wrongly seen as independent rather than interdependent. Furthermore, 
it is connected with a view of ethics that is separated from politics by a focus on 
individual decision-making – and exhibits a corresponding tendency to ignore how 
contexts of choice are formed, especially how institutions structure, enable and 
disable our choices. That is to say, some framing assumptions of philosophical ethics 
fit rather neatly – too neatly – with a focus on consent and other individual rights such 
as confidentiality. To put the point mildly, this makes it more difficult to frame 
discussion of issues that arise in collective action and decision-making – not least, in 
my context here, how medical research is organised and prioritised. However – this 
point is essentially to do with academic theorising, and has less explanatory power 
when it comes to practitioners’ and policy discourse, not to mention that of lay 
people. 
 
So far as lay people are concerned: None of my contentions here are meant to dispute 
how important are the protections and guarantees that informed consent provides to 
the subject of both treatment and research. The openness and choice signalled by 
informed consent procedures provide some protection for the subject’s basic interests, 
and perhaps some opportunity to choose in the light of h/er own values. For parents, 
proxy consent provides a means to protect their child(ren) in the face of organisations 
that are not always trusted. The provision of information makes for openness, which is 
at least a precondition in ensuring fairness as well as protection of interests. 
 
Some have argued that there is more to the story that this, and here we enter more 
ambiguous territory. One can see the practical emphasis on informed consent as fitting 
with a certain sort of self-conception. Investigation of what research subjects say – 
and of what people who refuse to participate in research also say – suggests that 
informed consent supports an image of the ‘responsible subject.’9 That is, it enables 
people to see themselves as moral and responsible, choosing in the light of a moral 
imperative to participate in research. This is true even of those who refuse to 
participate: it is only that they find that possible risks weigh more heavily than the 
duty to assist research. In short, informed consent fits well with our ideas of what it is 
to be a responsible person – and who does not want to see h/erself as responsible? 
 
This suggests that informed consent is serving, not the interests, but rather the self-
image of actual and potential research subjects. In itself, this may not sound 
particularly sinister. Protecting autonomy is protecting the right to choose in the light 
of one’s values; and we have good reason to hope that people will number social 
responsibility amongst those values. If mechanisms of informed consent encourage 
this, then this is only a sign that our ‘autonomy’ is necessarily limited by the 
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This raises the question, of course, as to how just those institutions and their divisions 
of responsibility may be. Part of seeing oneself as responsible is accepting 
responsibility; and it may be that subjects of research are finding themselves 
accepting more responsibility than they ought. Many have noticed that informed 
consent procedures can involve an imposition of responsibility upon the subject, as 
co-decider, co-responsible for the project – someone who becomes ‘concerned’ in 
both senses, participating and anxious. Neo-Foucauldians such as Nikolas Rose have 
analysed modern Western societies in terms of ‘responsibilisation.’ Thus Rose claims, 
‘individuals are not merely “free to choose,” but obliged to be free, to understand and 
enact their lives in terms of choice.’10 As a simple example, we might notice how 
many Western governments have preferred to target health interventions at 
individuals, rather than regulating the activities of commercial organisations. In the 
UK, childhood obesity has become a source of great concern, not to say moral panic. 
Thus far the response has been to emphasise parental responsibilities, and not (for 
example) to regulate the marketing of energy-dense foods by private enterprise. 
 
In the context of genetics, an emphasis on individual responsibility has often been 
seen as a guarantee against the bad old eugenics. This has been very clear in the case 
of genetic counselling, for instance, in advising couples concerning the possible 
transmission of genetic disorders to any children they may have. The professional 
ethos of genetic counselling has centred on non-directiveness – a purported refusal to 
impose medical or state values upon the subject (in direct contrast not only to 
eugenics but also to the conventional value-laden-ness of medical care).11 But this 
distancing of the state – or rather, of health care practitioners who may be funded by 
the state – from individual choice has a potentially invidious aspect. It can be, indeed 
sometimes is, experienced as a handing-over of responsibility to the parents, 
constituting a refusal to help, to share responsibility for what can be immensely 
difficult decisions.12
 
Returning to the context of medical research, this immediately suggests one reason 
why many subjects show so little recall of information about the project, and indeed 
may show very little interest in even “reading the form.” What you don’t know about 
can’t be an object of your responsibility – or so we commonly tell ourselves. Not 
knowing can operate as a way of refusing a (dimly perceived) imposition of 
responsibility. 
 
Consent procedures not only impose responsibility, for better or for worse. They can 
and do impose risks and costs on subjects.13 Informed consent procedures usually 
make clear that research subjects will not share in any profits or gains that stem from 
the research. Whatever its motivation, this clarification effectively functions as a 
renunciation of any possible entitlement to a share in profits or benefits. Thus 
informed consent forms become a contract clarifying future rights – or lack thereof. 
Sometimes consent forms will even disavow the researcher’s liability should certain 
risks to the subject materialise – a provision that is certainly against the subject’s 
interest and unquestionably to the benefit of the researcher’s host institution. In either 
case, as one writer puts it, ‘the consent becomes a waiver’14 – with regard to future 
risks to the subject, and future benefits to the researching institution. 
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These darker aspects of informed consent are increasingly well-recognised, in the 
bioethical literature at least. Another problem is simpler, cruder and larger than all of 
the above. A focus on informed consent is also highly convenient for researchers and 
their institutions, and above all commercial enterprises. The reason is simple: insofar 
as individual rights delimit the domain of ethics, they shield other substantive issues 
from critical scrutiny. Not the least of these is the most important factor distorting 
priorities for medical research in the world today: the transnational pharmaceutical 
industry, operating in a context of gross global injustice and often in the context of 
inadequate or ill-conceived national health care frameworks. Pursuing a pill for every 
lucrative ill, this is an industry more concerned with marketing than research, more 
concerned with markets than needs, more concerned to market treatments than to 
prevent ill-health. The industry naturally promotes a reductive, individualistic and 
remedial approach to health, one that governments, researchers and health 
organisations have too often fallen in with. In the face of this enormous problem, 
informed consent, or other individual rights, are no answer at all – worse, such a focus 
constitutes an obstacle to perceiving the problem at all. Too often, it seems that to talk 
about such large and overwhelming factors is to stop talking ethics and to start talking 
something less respectable – that is, politics, something which (it may be implied) 
neither researchers or bioethicists should concern themselves with.  
 
A second problem is related. If ethics is about consent or confidentiality, then ethics is 
no longer concerned with the scientific validity of research, gauging the likely 
benefits of research, and establishing priorities among well-grounded research 
possibilities. Evidently research ethics committees play an important role in 
addressing such issues at the micro level. Apart from the signal fact that this still 
leaves the macro level unaddressed, there remains the problem that ‘science’ and 
‘ethics’ can too easily come apart. If such committees see their ethical task as 
protecting individual rights, and their scientific task as scrutinising the validity and 
workability of proposals, then at least two results ensue. The fact that scientific 
validity is a moral demand tends to drop from sight: yet validity matters so much 
because we want effective health interventions. Second, the extent to which a research 
proposal is worthwhile comes back to the narrower question of whether it should be 
able to properly investigate its leading hypothesis. The narrowing of ethics to 
individual rights can thus operate to support technocracy,15 distancing assessment and 
decision-making from the perspectives and concerns of non-experts, and leaving 
‘ethics’ unable to challenge commercialism or other distorting factors in priority-
setting for medical research. The questions of whose health and whose interests will 
be served by research are too rarely asked, and need not be answered. 
 
In short, while there are certainly good reasons for valuing informed consent, there are 
also several bad reasons why we may be led to over-emphasise it – reasons that have 
nothing to do with protecting research subjects and which divert our attention from 
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Biobanking as a case study 
 
I turn now to the case of large-scale biobanking. Biobanking involves the storage of 
(i) tissue samples and/or genetic information and (ii) personal information, such as 
health care data (disease histories, treatments received), lifestyle information 
(nutrition, exercise, wealth, family background) and sometimes genealogy, or certain 
other sorts of identifying data. 
 
Biobanking is not a new phenomenon, but it has taken on a much greater significance 
with the emergence of research into genetics and the first practical applications of 
genetic knowledge. In fact, two of the most important applications of genetic 
knowledge have not been medical at all. As we know, we are still a very long way 
from decoding all but the most simple health information from a person’s genetic 
make-up (that is, chromosomal abnormalities and single gene disorders). What we can 
do is to use genetic samples to identify individuals and to identify basic genealogical 
linkages. At present, then, the most significant uses of genetic information are 
forensic investigation and paternity (or maternity) testing. Biobanking can then take 
two main forms: either to exploit these existing abilities, or as a basis for research to 
increase our understanding of the human genome and how its tiny variations between 
individuals might affect our bodily make-up and our health. 
 
Exploiting existing abilities, and correspondingly the most well-established of 
biobanks, are forensic biobanks. The UK’s National DNA Database is the largest in 
the world, with genetic profiles from just over three million people16 – it has doubled 
in size since 2002 and we are told to expect a similar rate of increase for the 
foreseeable future. When DNA samples can be extracted from traces left at crime 
scenes, they can be processed and the resulting ‘profile’ compared with the millions 
on record. Sometimes a match will occur, which can be invaluable in linking different 
crimes or in identifying a culprit. Sometimes too a sample can be taken from a suspect 
and shown not to match DNA that can be reliably identified with the crime: so 
suspects can be shown to be innocent, not just guilty. The UK also has a large 
database for paternity testing, so that financial responsibilities for childcare can be 
allocated to the biological father, where partnerships have broken up. This is much 
smaller, and I will leave it aside here. 
 
Of course, these sorts of biobank can also be used for various forms of research, 
however unclear the ethics of this might be. The greatest interest here has naturally 
been in deriving phenotypic information from a genetic sample, so as to aid 
identification of the person who has left traces at a crime scene – thus information 
about quantitative traits such as height; hair, skin and eye colour; or even facial 
characteristics. This research is still in its infancy, and other possible discoveries such 
as correlations between genetic make-up and behavioural traits (the ‘criminal gene’?) 




Genomics, Society and Policy, Vol.1 No.2 (2005) ISSN: 1746-5354 
© CESAGen, Lancaster University, UK.  
            Genomics, Society and Policy 
            2005, Vol.1, No.2, pp.50–66. 
The other forms of biobanking are principally concerned to increase our knowledge of 
how genetic variation influences body and health. One older form of biobanking, 
which I will not be concerned with here, is simply the storage of human tissues from 
people suffering from particular disorders. This has been going on for a long time, 
because there are many properties of tissues that are more immediately and obviously 
relevant to health than DNA. These banks tend to be relatively small, spread out 
across the health service and private companies, and are often not documented, many 
being built up by individual researchers in the course of their careers. These disease-
specific banks, apart from not being principally concerned with genetic research, are 
also close to conventional medical research in that it is samples and data from the 
unwell that are used. Often the data will be gathered post-mortem, which also means 
it can effectively be anonymised and does not raise so many issues of individual 
rights. (However, it can raise profound concerns about parental rights, as we saw in 
the UK’s Alder Hey scandal, when organs from dead children were taken for research 
without parents’ understanding.) 
 
Neither the involvement of the unwell, nor even the deceased, apply to the two forms 
of biobanking which I would like to consider alongside the forensic case. In these 
cases, samples and information are taken from many people, most of whom are not 
suffering any particular disease or disorder. The information, and perhaps samples 
too, are taken on an on-going basis. 
 
The examples that have attracted the most attention, perhaps because of their sheer 
scale and novelty, are the large-scale biobanks for adult medical research. The most 
well-known, and the furthest along the path to being realised, is the Icelandic genetic 
database. This is a complicated arrangement, which was originally supposed to be 
made up of three different databases, and has several distinctive features: 
 
• Samples and genetic information, and genealogical information are being 
entered onto two separate but linked databases. Originally a further database 
of health care data was conceived, the Health Sector Database, but it now 
appears unlikely that this will be created. 
 
• The whole population is included in the genealogical database (around 
290,000 people in 2004); consent is not involved as this uses existing public 
data. The database of genetic samples is gathered on the basis of informed 
consent. The Health Sector Database was enormously controversial because it 
presumed consent – that is, health data was to be gathered automatically, 
except from those who specifically opted out.17 
 
• The resulting database is under exclusive licence to a commercial enterprise, 
deCode genetics. 
 
These last two aspects have made the Icelandic database especially controversial, in 
that informed consent was to have been waived for health data collection, and that the 
research agenda is being shaped by a private company – which is, of course, hoping to 
profit from any findings. 
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Almost as well-known is UK Biobank, a major initiative currently in its pilot stages.18 
This is supported by the UK government, the Medical Research Council, and the 
Wellcome Trust (the world’s largest medical research charity) at a projected cost of 
£60 million (and many suggest this will represent only the initial costs). It will gather 
samples and data from half-a-million people, aged 40-69 – most of whom will be 
healthy but many of whom will develop some of the major diseases of Western 
societies – heart disease, cancer and so on – in the next decades. Consent will be 
asked, and there will be no exclusive licence to a commercial enterprise, though 
private companies will have access to the biobank, on terms yet to be established.  
 
Finally, I want to mention a third type of research biobank, smaller and better 
established than the large-scale adult databases just mentioned. Various child-cohort 
studies exist around the world. The UK has two important examples. In Bristol, there 
is the Avon Longitudinal Study of Parents and Children, ALSPAC, otherwise known 
as the ‘Children of the 90s’ study. This includes information about 14,000 children 
born in the early nineties, as well as their mothers and fathers. Biological samples, 
medical information and lifestyle information are gathered on a regular basis from all 
the children. By stark contrast with UK Biobank, this project has been funded on a 
shoe-string, by small, discontinuous grants from the various UK funding bodies. 
There is also the North Cumbria Community Genetics Project, which is more 
narrowly directed toward genetic studies, with samples from about 5,000 children and 
their mothers. 
 
The scale of the Iceland database and UK Biobank can only partly explain the 
attention they have received. After all, the UK’s National DNA Database is far larger 
than both combined, and much longer established; this is true of forensic biobanks in 
other countries too.19 The child cohort studies are also much better established, 
having been up and working for over a decade. I would like to suggest that the greater 
attention devoted to these new, largely speculative projects has arisen not only 
because of their scale but because they are more congenial to our framing assumptions 
about ethics. Although the large adult biobanks unquestionably pose difficulties for 
our established ethical framework for medical research, they are by no means as 
problematic as the forensic and child cohort cases, because informed consent remains 
an important and relevant issue.20 (So too confidentiality, but this is a concern for all 
my examples.) Nonetheless, consent serves us badly as a point of orientation for the 
adult medical banks, as well as being nigh-on useless in the child and forensic cases. 
The larger, better-established forensic databases can help us meet this difficulty, 
because in these cases it is self-evident that not consent but public policy principles 
(such as institutional oversight) and competing political priorities (eg, crime detection, 
limiting state surveillance) must provide the framework for our thinking. Here we can 
no longer maintain artificial divides between the ethical and the political, between 
individual rights and public goods 
 
Why are individual rights, to consent or confidentiality, inadequate to the new large-
scale research biobanks, like Iceland’s or UK Biobank? I suggest the answer is 
relatively straightforward. They transcend our usual examples of medical research in 
three important respects: (1) These projects are prospective and open-ended by their 
very nature, and necessarily are very broad and indeterminate in their research 
purposes; (2) Most of the research subjects will not be ill; in many respects, moreover, 
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it would be better to begin with children rather than adults; (3) Their sheer scale 
means that they evade our standard mechanism for ensuring that individuals 
participate in well-designed research, the research ethics committee. I will comment 
on the first and second points in turn; the question of how well-conceived the research 
biobanks arises as an important issue for both. 
 
With regard to the prospective nature of the studies: The biobanks require an on-going 
contribution from the research subject. If not samples, then at least health information 
and possibly lifestyle data should be entered into the bank over an indefinite period of 
time – ideally, until death, or, rather, post-mortem. This has, in turn, two important 
implications. First, complete anonymisation of data is impossible, as this would 
prevent new data being linked to the old, and to the tissue sample or genetic 
information. The best we can do is to code data, and entrust linkages to a secure 
bureau or trustee. (As the forensic databases remind us, genetic information is in 
principle never securely anonymous.) This means that there are always risks to 
subjects in terms of breaches of confidentiality, and there are many interested parties 
such as insurance companies, employers and even state agencies who might use such 
information against subjects’ interests. Of course, these risks are likely to increase 
over time, to the extent that we become better able to interpret individual genetic 
variations. 
 
Second, and more important from the point of view of consent: it is necessarily 
impossible to inform research subjects about the nature of the research that will be 
conducted with the biobank. As our knowledge increases, we can hope to investigate 
much more with the information banked, but what that ‘much more’ will be no one 
can say. However – and this point is by no means incidental – this is not just a 
problem of inevitable ignorance on the part of scientists and subjects. (After all, there 
will always be ignorance about the future outcome of any meaningful research study.) 
It also relates to an on-going problem of overstatement regarding the projected uses 
and findings of the biobanks. We are being promised all sorts of knowledge and 
benefits, yet these promises are often vaguely articulated and, on examination, frankly 
implausible. 
 
This implausibility begins with the major practical issue for any study of such a scale: 
how to obtain and process sufficiently detailed and accurate information concerning 
the lives, health and changes in physical condition of the research subjects. Though 
some lifestyle and environmental factors, such as smoking, are fairly easy to record, 
others, such as diet, alcohol intake and physical activity are more complex and 
problematic (self-reporting is notoriously unreliable), so too psychosocial variables. 
Similarly, medical information is extremely difficult to gather and codify except in 
categories that will often be too wide for meaningful comparison. Measurements of 
simple physical variables such as blood pressure need to be repeated if research 
subjects are to be compared informatively, while repeated measurements of more 
complex variables – anything from glucose levels to cholesterol to blood cell counts – 
will be extremely costly on such a scale. Thus greater understanding of the 
connections between genetic variations and disease susceptibility is only likely to 
arrive in the most crude and unhelpful forms. Smokers with these genetics variants 
and a diet including meat (Which meats? Eaten how often? And with what?) have – 
on average – an x% higher risk of heart disease.  
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At least some of these issues can be overcome with sufficient resources. Behind them, 
however, stands the well-known yet neglected fact that the diseases most often 
mentioned in connection with the medical biobanks are diseases of Western societies 
– that is, diseases whose causation can only have a slight basis in genetic variations, 
and are overwhelmingly related to socio-economic, environmental and lifestyle 
factors.21
 
These obvious scientific difficulties have not discouraged highly speculative 
suggestions about the findings and technologies that might result from biobank 
research. Two in particular recur in the literature. We are promised 
pharmacogenomics – drugs ‘tailored to each individual’s genetic constitution’ – and 
population genetic screening – the possibility of screening for susceptibility to various 
diseases, with the promise that preventative measures can then be tailored to 
individuals. Both seem unlikely to materialise and unlikely to generate significant 
benefits if they do. Consider population screening: we may find out that some 
individuals have a higher risk of some sort of heart disease should they fail to exercise 
regularly as compared to others. The obvious preventative measure is regular exercise 
– something which we should all undertake anyhow. More speculative measures 
include drugs that will have a prophylactic effect – ‘pills for the healthy ill,’ as they 
have been ironically christened – with the attendant costs of testing and the risks of 
any pharmaceutical intervention. None of this looks likely to represent good value for 
money from a public health perspective.22
 
So far as pharmacogenomics is concerned: there may be some basis for expecting 
some useful tests for some particular (classes of) drug, but the overall benefits are 
likely to be relatively slight. So far as the cost-benefit ratio of any test that does 
emerge is concerned, the issues here are twofold. First, most adverse drug reactions 
arise from dosage problems, interactions with other drugs or environmental factors, or 
physiological problems such as impaired liver or kidney function. Second, many 
problems of intolerance or non-response to drugs will therefore not be predicted by 
genetic tests, which in any case are likely to yield only probabilistic information, so 
that the need for careful monitoring of a patient’s drug response will not be 
diminished. Both of these difficulties would apply even if it proved relatively 
straightforward to identify pertinent genetic variations and turn them into a cheap, 
reliable test.23
 
Clearly much more might be said with regard to these difficulties, but the broad 
problems with both sets of promises are easy to see. I mention them here for two 
reasons. First, as regards the ‘informed’ part of consent, they suggest that subjects are 
liable to be misled about the broad terms of the biobanks they join.24 Second, they 
point us to issues that go much beyond those individuals – above all, to the question 
of whether these projects are scientifically well-justified and reasonable value for 
money, as against the many other ways we might invest in health and health research. 
It is interesting, moreover, that the biobanks’ ambitions are notably congenial to 
pharmaceutical companies (in terms of markets for genetic tests and prophylactic and 
remedial drugs), despite the fact that most large-scale medical biobanks are heavily 
reliant on public funding. It seems that a reductive, individualistic and medicalised 
approach to health is dominating our thinking about genetic research – despite the fact 
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that this research is essentially collective in nature, despite the fact that genetics might 
just as well remind us how much human beings have in common and how greatly 
variations between people must be attributed to non-genetic factors. 
 
To turn, now, to a second important respect in which large-scale medical biobanking 
differs from conventional medical research: Most of the participants will not be 
suffering any particular illness. This is advantageous from the point of view of 
consent, both so far as adult subjects and parents of child subjects are concerned: not 
experiencing the strain of illness and not needing to be grateful for present health care, 
people are more able to attend to the research proposal and less likely to feel 
pressured into participating. The disadvantage of this, however, is that research 
subjects are much less likely to take an active interest in the research being done – 
that is, to feel responsible for ensuring research is done that reflects their interests. 
Over the past two decades, we have increasingly seen patient groups forming (albeit 
sometimes with the connivance of pharmaceutical companies), who have lobbied for 
research into their conditions: I have already mentioned the crucial role of patient 
activism, and more broadly gay activism, in HIV/AIDS research. We surely cannot 
expect participants in UK Biobank to take to the streets to ensure that this resource is 
used for the public interest; at most, there may be a tendency for subjects to withdraw 
their participation if it becomes clear that a biobank is not being used for ends they 
can endorse.25
 
In addition to being mostly well, there is a case for thinking children would make 
more suitable subjects, so long as we want to give due weight to environmental 
factors. In particular, if we want to know about the explosion of allergies, asthma and 
food intolerances, or about conditions that promise premature death such as diabetes 
and obesity, then we need to know an awful lot about the details of childhood 
development, including development during pregnancy.26 As with the common causes 
of mortality mentioned in connection with the adult biobanks, these are obviously not 
disorders with a substantial genetic basis. Furthermore, the findings of such studies 
are unlikely to point to pharmaceutical interventions. Most probably such 
interventions will consist in broad public health measures, likely to be lower in risk, 
cheaper per person and more beneficial to everyone – apart, one is tempted to add, 
from those with an interest in selling more medical drugs or tests. 
 
It is quite clear that informed consent is barely relevant to justifying child-cohort 
studies, and it is at least arguable that our preoccupation with consent has undermined 
them – making child research appear much more problematic than need be. (I have 
already mentioned how badly funded such projects have tended to be; the disparity in 
funding between these and UK Biobank is especially notable.) If such projects are to 
be justified, consent must of course play a role – to start with, parental consent, and 
later and increasingly, the children’s consent. Here consent is operating not so much 
to protect children’s interests, which must be an important duty on the part of those 
designing and managing the study, but rather to ensure trust and to promote fuller 
participation. (The sort of detailed information required about subjects cannot, after 
all, be discovered without the willing involvement of parent as well as child.) But 
beyond consent, and still more important, is scrutiny of the research undertaken using 
the data – whether it is well-conceived and likely to yield meaningful knowledge and 
benefits. The crucial question must be the soundness of the project in toto – whether it 
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really brings together data of the detail and quality needed to investigate lifestyle-
environment-health interactions (with the possibility of investigating genetic factors 
where this seems likely to be fruitful), whether it is really likely to yield cost-effective 
measures to improve health. 
 
It is useful, too, to remember the forensic databases, where genetic knowledge is 
being exploited for non-health purposes. Here, no one talks about consent, which 
would render the collections barely useful; samples are usually taken on a statutory 
basis. What has been important in justifying such databases is not individual rights but 
the public interest in detecting the culprits of violent crimes. Especially the 
association of DNA samples with sexual offences has made this justification 
overwhelmingly persuasive to the public. This does not mean that many critical points 
should not be made about forensic databases.27 Here we lack not only the limited 
protections afforded by consent procedures but also the other well-developed checks 
of medical and research ethics – above all concerning confidentiality, scrutiny of 
research proposals and institutional oversight. These databases represent a huge 
growth in potential state power. Costs (as benefits) to individuals can be very severe, 
and abuses or infringements of individual rights are easy to imagine. Here, again, one 
may fear that a seductive ‘genetic fix’ is at work: some worry that genetics is 
diverting attention from careful forensic work; in any case, such a database is hardly 
preventative of crime and its overwhelmingly social causes (although we might hope 
that the databases will develop some deterrent effects).  
 
Nonetheless, there is widespread recognition that we should think about forensic 
databases in political terms such as the public interest, the extent of state power, and 
checks and balances such as (presently lacking) institutional oversight mechanisms to 
regulate access and usage. Much less is said about the forensic banks: this is partly 
because it is much more difficult to investigate their workings, and partly because 
they fall less than squarely within the conventional domain of bioethics. But I have 
also pointed to a less welcome explanation: might this neglect not also reflect the 
indubitable fact that they raise significant political questions – questions which 
expose the narrowness of ‘ethics’ as it is commonly understood? So long as we do pay 
attention to the forensic banks, however, we will have no doubt that large-scale 
biobanking raises important policy and political issues, issues which cannot be dealt 
with by focussing on individual rights. Not the least of these – as in the forensic case, 
as in the justification of studies on children who cannot meaningfully consent – will 
be whether the banks represent a worthwhile priority, liable to generate knowledge 
and benefits on a scale commensurate with the investment they demand. 
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Conclusion 
 
Most bioethical writing on biobanking recognises some of the limitations of a 
framework based on individual rights, and there have been repeated calls for other 
principles to frame the issues. Some candidates that have been offered include 
solidarity, altruism (the ‘gift relationship’), benefit-sharing and ‘governance.’ These 
concepts have made some impact on public and policy discourse, but have often been 
taken up in a frankly instrumental way – ‘gift’ being a well-documented example, 
whereby subjects get moral credit and nothing else in return for their participation.28
 
The first part of my discussion argued that informed consent is an ideal whose 
practice has turned out to be more complicated and ambivalent than one would wish. 
This is no more than one might expect when an ideal is pulled into practice: situated 
amid competing interests and diverse institutional imperatives, deployed in contexts 
which were quite unthought of when it was originally coined. We might suspect that 
other general principles are liable to meet similar fates: a duty to participate in 
collective research, a notion of altruistic donation, the imperative for just sharing of 
benefits, and the importance of institutional regulatory mechanisms – these are all 
ideas with clear validity, but their limits are not difficult to see. Moreover, none of 
them really highlight the central questions that biobanks pose: How well-conceived is 
this line of research? What will its benefits be? Why this research and not something 
else? How are we organising and funding research? Nor do they help us uncover the 
presuppositions we may be making about the nature of health and ill-health: I have 
only alluded to a few of the problems involved in conceiving of health in individual, 
genetic, and medicalised terms. No one can believe that this is anything like the whole 
story about health, but as an unexamined assumption it is surely a powerful factor in 
keeping (bio)ethics away from political and economic factors. 
 
Be that as it may, the more immediate motivation for my argument here has been the 
fear that the new large-scale medical biobanks will prove wrong-headed ventures, 
which will generate relatively little basic knowledge and few useful applications. 
Certainly, they seem unlikely to take us much closer to key sources of chronic ill-
health, nor to generate population-wide measures that tackle common causes of 
premature death. We may end up thinking of UK Biobank as the Millennium Dome of 
British medical research, a glamorous white elephant, expensive but of little use. 
However much UK Biobank may not infringe individual rights, it has been too large 
to be caught by less commonly mentioned research safeguards such as scientific peer 
review. This assessment may be overly pessimistic. But I think my central argument 
will still stand: that ‘ethics’ must engage important questions about what is being 
researched and why, about our priorities for publicly funded research, about how 
research is organised and funded. Informed consent is much too close up for us, or 
research subjects, to see this question: its limitations should remind us of the huge 
power differentials between individual research subject and researching organisations. 
Likewise, the net of research ethics committees and scientific peer review is also too 
close to catch such issues, which concern the aggregate picture. Yet the worse reasons 
for the enduring popularity of informed consent may remind us that there are powerful 
factors at work in keeping ‘ethics’ away from these questions. 
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